Maze Therapeutics (NASDAQ:MAZE) Releases Earnings Results, Misses Estimates By $10.72 EPS

Maze Therapeutics (NASDAQ:MAZE) posted its earnings results on Monday. The company reported ($18.32) EPS for the quarter, missing the consensus estimate of ($7.60) by ($10.72), Zacks reports.

Maze Therapeutics Trading Up 1.3 %

Shares of Maze Therapeutics stock opened at $11.42 on Monday. Maze Therapeutics has a 1 year low of $9.88 and a 1 year high of $17.00.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on MAZE. Guggenheim started coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued a “buy” rating and a $19.00 price objective on the stock. Leerink Partners assumed coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $28.00 price target on the stock. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. Leerink Partnrs upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. Finally, JPMorgan Chase & Co. began coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set an “overweight” rating and a $30.00 price target on the stock. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $25.67.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.